Psychemedics (PMD) News
Market Cap: $13.45M
Avg Volume: 34.34K
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Related Tools
🗞️ Stock News Assistant
Get concise summaries, analyze trends, and ask questions about stock-related news.
Use Tool✍️ AI Journalist
Input a topic and GPT will search the web, find relevants articles, and write an article based on the research.
Use Tool
Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing
DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report.
globenewswire.com
Read More
Psychemedics Corporation Reports Second Quarter 2024 Financial Results
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024.
globenewswire.com
Read More
Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock
DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has recommended, and the Board has approved, a plan to cease the registration of the Company's common stock under the federal securities laws following the completion of a proposed reverse stock split and to delist its shares of common stock from trading on the Nasdaq Capital Market. It is expected that this plan would be effectuated in the fall of 2024, assuming the approval of Psychemedics' stockholders at the Company's 2024 Annual Meeting of Stockholders, among other things, as described below.
globenewswire.com
Read More
Psychemedics Unveils Inaugural Insights Report:Â Revealing Drug Trends Through Hair Testing
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023.
globenewswire.com
Read More
Psychemedics Corporation Reports First Quarter 2024 Financial Results
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024.
globenewswire.com
Read More
Psychemedics Corporation Reports 2023 Financial Results
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023.
globenewswire.com
Read More
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider
Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics' commitment to excellence and innovation in the field of employee health testing.
globenewswire.com
Read More
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing.
globenewswire.com
Read More
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance.
globenewswire.com
Read More
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023.
globenewswire.com
Read More
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen
Psychemedics debuts a 5-panel drug test replacing marijuana with fentanyl, the first hair drug test exclusively targeting the most dire workplace threats.
globenewswire.com
Read More
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer
ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies.
globenewswire.com
Read More
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards were granted on August 17, 2023, Mr. Hullinger's hire date as the Chief Executive Officer, and also the date on which he was elected to the Psychemedics Corporation Board of Directors. The options have a ten-year term and an exercise price of $4.65 per share, the closing price per share of Psychemedics Corporation common stock as reported by Nasdaq on August 17, 2023. The options were awarded in three tranches. Under the first tranche, option awards covering up to 100,000 shares vest over two years, with 50% of the original number of shares underlying the option vesting on the one-year anniversary of the date of grant and 50% on the two-year anniversary of the grant, subject to Mr. Hullinger's continued service with the Company through the applicable vesting dates. Under the second and third tranches, options to acquire 100,000 shares each were granted and each becomes exercisable in full only upon the attainment and continuation in effect for a specified period of time of a particular stock price on the Nasdaq Stock Market.
globenewswire.com
Read More
Psychemedics Corporation Reports Second Quarter 2023 Financial Results
ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023.
globenewswire.com
Read More
Psychemedics Corporation Announces CEO Succession Plan
Brian Hullinger Will Succeed Ray Kubacki as CEO Effective August 17, 2023 Mr. Hullinger Brings 30 Years of Leadership Experience and a Proven Track Record of Driving Growth ACTON, Mass.
globenewswire.com
Read More
Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play
21% YoY revenue growth in Q4, gross margins surge 1,000 bps YoY. EPS loss of $0.29 on higher legal costs and a one-time expense.
seekingalpha.com
Read More
Small And Microcap Newsletter: DHT Holdings Financials Give It Time Until The Next Tanker Bull Market
In this week's newsletter, we look at a company in the middle of monetizing its major asset to see what is left after the deal closes. We also review a shipping company that has built a strong margin of safety.
seekingalpha.com
Read More
Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend
29% YoY revenue growth in Q3, margins surge.
seekingalpha.com
Read More
Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target
Market-leading drug testing company, 30 years history, drug abuse increasing in the US. 13x P/E, 8% FCF yield on “normal” 2023 estimates.
seekingalpha.com
Read More
Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results
ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021.
globenewswire.com
Read More
Montana Advisors Writes Open Letter to Psychemedics
MIAMI--(BUSINESS WIRE)---- $PMD--Montana Advisors issues open letter to Psychemedics CEO (Nasdaq: PMD): Dear Kubacki: It was a pleasure speaking with you two months ago via Zoom. I appreciate the time you have given me to discuss Psychemedics Corp. (PMD or the “Company”). As you know, I continue to believe that PMD shares continue to trade at a significant discount to their intrinsic value. Montana has made recommendations on ways to unlock the value of the shares, including making your balance sheet wo
businesswire.com
Read More
Psychemedics Corporation Reports First Quarter 2021 Financial Results
ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2021.
globenewswire.com
Read More
Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results
ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020.
globenewswire.com
Read More
Robyn C. Davis Joins Psychemedics Board of Directors
ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing this past December of Clint Allen, a long- time and dedicated Psychemedics board member.
globenewswire.com
Read More
Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller
ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek has joined the Company as Vice President, Controller.
globenewswire.com
Read More
Psychemedics Announces Third Quarter Results
ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020.
globenewswire.com
Read More